Aims/hypothesis We investigated associations of allelic variations in the WFS1 gene with insulin secretion and risk of type 2 diabetes in a general population prospective study. Methods We studied 5,110 unrelated French men and women who participated in the prospective Data from Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Additional cross-sectional analyses were performed on 4,472 French individuals with type 2 diabetes and 3,065 controls. Three single nucleotide polymorphisms (SNPs) were genotyped: rs10010131, rs1801213/rs7672995 and rs734312. Results We observed statistically significant associations between the major alleles of the three variants and prevalent Diabetologia (2011) 54:554-562 DOI 10.1007/s00125-010-1989 type 2 diabetes in the DESIR cohort at baseline. Cox analyses showed an association between the G-allele of rs10010131 and incident type 2 diabetes (HR 1.34, 95% CI 1.08-1.70, p=0.007). Similar results were observed for the G-allele of rs1801213 and the A-allele of rs734312. The GGA haplotype was associated with an increased risk of diabetes as compared with the ACG haplotype (HR 1.26, 95% CI 1.04-1.42, p=0.02). We also observed statistically significant associations of the three SNPs with plasma glucose, HbA 1c levels and insulin secretion at baseline and throughout the study in individuals with type 2 diabetes or at risk of developing diabetes. However, no association was observed in those who remained normoglycaemic at the end of the follow-up. Associations between the three variants and type 2 diabetes were replicated in cross-sectional studies of type 2 diabetic patients in comparison with a non-diabetic control group. Conclusions/interpretation The most frequent haplotype at the haplotype block containing the WFS1 gene modulated insulin secretion and was associated with an increased risk of type 2 diabetes.
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Introduction
Wolframin (WFS1) is a transmembrane protein of the endoplasmic reticulum (ER), found ubiquitously but with higher levels in pancreatic beta cells and specific neurons of the central nervous system [1] . WFS1 is a component of the unfolded protein response following ER stress [2] . It controls a negative regulatory feedback loop of the ER stress signalling network, acting as an ER stress signalling suppressor [3] . ER stress signalling is tightly regulated in pancreatic beta cells to produce appropriate amounts of insulin in response to the frequent fluctuations of blood glucose levels [4, 5] . WFS1 is upregulated during insulin secretion and plays an important role in maintaining ER homeostasis and cell integrity in pancreatic beta cells [2] . Inactivation of the wolframin gene (Wfs1) in beta cells of rodents causes ER stress and beta cell death by accelerated apoptosis [2, 3, 6] . Mutations in WFS1 are responsible for Wolfram syndrome [7, 8] , a rare recessive disorder characterised by diabetes mellitus, optic atrophy and other neurological and endocrine abnormalities [9] . An increased prevalence of diabetes mellitus was reported in first-degree relatives of patients with Wolfram syndrome [10] , suggesting a possible effect of WFS1 mutation heterozygosis. More recently, common variants of WFS1 were shown to be associated with type 2 diabetes in populations of European descent [11] [12] [13] . Associations of these variants with insulin secretion in response to oral or intravenous glucose was observed in some [14, 15] , but not all studies [16] [17] [18] . In the present study, we investigated associations of allelic variations in the WFS1 gene with insulin secretion, insulin sensitivity and the risk of hyperglycaemia (impaired fasting glucose [IFG] ) and of type 2 diabetes in a 9 year population-based prospective cohort. We tested the hypothesis that discrepancies in the associations between WFS1 variants and insulin secretion in previous reports could be related to differences in glycaemic and/or diabetes risk status of studied populations. For the purpose of replication, associations between WFS1 variants and diabetes were also investigated in three independent type 2 diabetes crosssectional cohorts.
Methods
Participants in prospective study: the DESIR cohort The Data from Epidemiological Study on the Insulin Resistance syndrome (DESIR) study was a 9 year prospective study conducted in 5,212 men and women from the French general population [19, 20] . Participants were recruited in ten healthcare centres in the western central part of France on the occasion of periodic health check-ups offered by Social Security. The study protocol included clinical and biological evaluations at inclusion and at visits after 3, 6 and 9 years of follow-up. Glycaemic status was classified in three groups, defined on the basis of fasting plasma glucose (FPG) and hypoglycaemic medication. Normal fasting glucose (NFG) was defined as FPG <6.1 mmol/l and IFG as FPG between 6.1 and 6.99 mmol/l, in the absence of treatment with a hypoglycaemic agent for both classes. Type 2 diabetes was defined as FPG ≥7.0 mmol/l or as FPG <7.0 mmol/l in the presence of treatment with a diabetes drug and a previous diagnosis of diabetes. The research protocol was approved by the ethics committee of Bicêtre Hospital and all participants signed an informed consent form. At baseline, 4,634 individuals (88.9%) had NFG, 342 (6.6%) IFG and 134 (2.6%) diabetes. The glycaemic status of 102 participants (1.9%) could not be ascertained at baseline and they were excluded from the analyses. NFG individuals lost during follow-up and whose final glycaemic status could not be determined (n=1,003) were excluded from the analyses of incidence. For the purpose of this investigation, we have considered the incidence of type 2 diabetes and the incidence of hyperglycaemic events (NFG to IFG, NFG to diabetes or IFG to diabetes change) during follow-up. The incidence of type 2 diabetes was 5.1% (203 cases out of 3,973 NFG or IFG cases at baseline), while the incidence of hyperglycaemic events was 16.7% (663 cases out of 3,973 NFG or IFG cases at baseline).
Participants in cross-sectional studies: DIABHYCAR, DIA-BHYCAR Gene and NCH cohorts The Diabetes, Hypertension, Cardiovascular Events, and Ramipril (DIABHYCAR) study was a 6 year double-blind multicentre multinational clinical trial conducted in 4,912 men and women who had type 2 diabetes, were aged 50 years or older at baseline and were selected on the basis of persistent micro-or macroalbuminuria without renal failure. The trial tested in a parallel design and vs placebo whether a low dose of ramipril that was able to reduce urinary albumin concentration would also reduce cardiovascular and/or renal events such as myocardial infarction, stroke, acute heart failure, end-stage renal failure and cardiovascular death. The study design, methods and results of the trial (which were negative regarding the drug effect) have been published previously [21, 22] . DNA banking was undertaken for the 3,137 participants recruited in France. The DIABHYCAR Gene cohort was recruited concomitantly to DIABHYCAR. It included 607 men and women with type 2 diabetes, aged 50 years or older at baseline and not presenting with microor macroalbuminuria. The study protocols of the two cohorts were approved by the Angers University Hospital Ethics Committee. The Necker and Cochin Hospitals (NCH) cohort included type 2 diabetic men and women consecutively recruited at the diabetes departments of NCH in Paris [23] . The present investigation included 728 individuals of European descent. Clinical and biological data were obtained from medical records. The study protocol was approved by the Ethics Committee of Hôpital Necker. For the purpose of these cross-sectional studies, the three cohorts of type 2 diabetic patients were compared with a control group of 3,065 participants from the DESIR cohort who had remained normoglycaemic at the 9-year follow-up (DESIR controls). This group from the French general population has been extensively used as a control group in genetic studies [24, 25] .
DNA studies The WFS1 gene spans ∼33.4 kbp on chromosome 4p16 and is contained in a single haplotype block. Three single nucleotide polymorphisms (SNPs) were genotyped using assay by design kits from Applied Biosystems (Life Technologies, Carlsbad, CA, USA): rs10010131 (G>A, intron 4), rs1801213/rs7672995 (G>C, R228R, exon 6) and rs734312 (A>G, H611R, exon 8). The SNPs were chosen in HapMap on the basis of capturing information on ∼80% of the allelic variation of SNPs with minor allele frequency ≥5% at r 2 >0.8 in the haplotype block containing WFS1.
Computations and statistical analyses HOMA index of beta cell function (HOMA%B) and of insulin sensitivity (HOMA%S) [26] , based on fasting levels of glucose and insulin, were computed using the Microsoft Excel spreadsheet implementation of the HOMA Calculator (v2.2) available at www.dtu.ox.ac.uk/Homacalculator/download. php (accessed 1 March 2006). Before genotype-related statistical analyses were performed, genotypes were verified to be in Hardy-Weinberg equilibrium in all groups of participants. Genotype associations with diabetes or hyperglycaemia were assessed by regression models. Cox proportional hazards survival regression analyses were used to examine the effect of explanatory variables on timerelated survival (disease-free) rates in prospective analyses. Kaplan-Meier curves were used to plot survival (diseasefree) rates over time according to genotype. Logistic regression analyses were used for cross-sectional analyses. Hazard ratios or odds ratios, respectively, with 95% CIs, were computed in these analyses for the risk allele. Adjustments for clinical and biological variables were carried out by including these variables as covariates in the regression model. The study had power >0.99 to detect associations of the SNPs with the incidence of diabetes in the DESIR study (for HR ≥1.2 and α=0.05) and with the prevalence of diabetes in the cross-sectional study (for OR ≥1.3 and α= 0.05). It had power >0.80 (for α=0.05) to detect differences in quantitative traits >10% between groups.
Comparisons of anthropometric, clinical and biological phenotypes between groups were assessed by ANOVA, analyses of covariance, contingency [27] .
Results
Prospective study: DESIR cohort Prevalence studies were conducted in 5,110 participants from the DESIR cohort (Table 1 ). The combined prevalence at baseline of IFG/ diabetes according to genotype was: 10.3% (GG), 9.3% (GA) and 7.5% (AA) for rs10010131; 9.8% (GG), 9.3% (GC) and 7.5% (CC) for rs1801213; and 10.4% (AA), 9.4% (AG) and 7.8% (GG) for rs734312. Logistic regression analyses showed associations of the major allele of the three variants with diabetes and with the combined prevalence of IFG/diabetes at baseline (Table 2) . When we considered the prevalence of IFG only, associations were also observed for rs10010131 and rs734312, while only a trend towards an association was observed for rs1801213 ( Table 2) .
The main baseline characteristics of incident cases of type 2 diabetes or hyperglycaemic events are shown in Electronic supplementary material (ESM) Table 1. The incidence of type 2 diabetes according to genotype was: 5.5% (GG), 5.4% (GA) and 3.6% (AA) for rs10010131; 5.2% (GG), 5.4% (GC) and 3.3% (CC) for rs1801213; and 5.5% (AA), 5.6% (AG) and 4.0% (GG) for rs734312. This suggests a dominant effect of the major allele for all SNPs (Fig. 1) . Cox proportional hazards survival regression analyses showed a statistically significant association between the G-allele of rs10010131 and the incidence of type 2 diabetes (HR 1.34, 95% CI 1.08-1.70, p=0.007 for a dominant GX vs AA model; 17 .7% (AG) and 15.9% (GG) for rs734312. Cox proportional hazards survival regression analyses showed a trend towards an association between the G-allele of rs1801213 and the incidence of hyperglycaemic events (HR 1.11, 95% CI 0.99-1.25, p= 0.08 for a co-dominant additive model) (ESM Table 2 ), while no association was observed for the other variants.
We assessed the impact of the SNPs on intermediate phenotypes such as FPG, HbA 1c , fasting insulin, and HOMA%B (insulin secretion) and HOMA%S (insulin sensitivity) indices. Analyses were performed with baseline values and with all available values collected throughout the study (baseline plus values at 3, 6 and 9 year visits). Results at baseline for rs10010131 genotypes are shown in Table 4 . These phenotypic analyses revealed a strong interaction between genotype and glycaemic status at the end of the study (NFG or IFG/diabetes). Genotype-related effects on intermediate traits were observed in the subset of the population presenting with IFG or diabetes at the end of the study, but not in individuals with NFG. In the former subset of the population, significantly higher FPG and HbA 1c levels and lower HOMA%B levels were observed in carriers of the GG risk genotype than in AA carriers. HOMA%S was not significantly different between groups. The exclusion of participants receiving sulfonylurea (n=15), metformin (n=15) or both (n=12) had no significant effect on the computations. Comparable results were observed when we considered the values of these variables collected throughout the study (ESM Table 3 ). Similar results were also observed for the other two SNPs, both at baseline and throughout the study (data not shown).
Cross-sectional study: DIABHYCAR, DIABHYCAR Gene and NCH cohorts Clinical characteristics of participants from the type 2 diabetes cohorts and from the control cohort are shown in ESM Table 4 . A logistic regression analysis was performed for each SNP with the cohort membership as the dependent variable, genotype as independent covariable, and sex, age and BMI as adjustment covariables. Odds ratio associated with genotype was computed for each type 2 diabetes cohort against the control cohort (ESM Table 5 ). Statistically significant associations of the major allele of the three variants with diabetes was confirmed in all type 2 diabetes cohorts individually, as well as with pooled data of the three cohorts. Linkage disequilibrium between the variants was computed and haplotype frequencies were determined for patients and for controls. A logistic regression analysis was performed with glycaemic status as the dependent variable, the haplotypes as independent covariable, and sex, age and BMI as adjustment covariables (ESM Table 6 ). The GGA haplotype (major allele of the three variants) was significantly associated with diabetes compared with the ACG haplotype (minor alleles of the variants).
Discussion
We observed statistically significant associations of the major alleles of rs10010131, rs1801213 and rs734312 in the WFS1 locus with an increased risk of type 2 diabetes in individuals with NFG or IFG in a 9 year prospective study in a French cohort issued from the general population. Only a trend towards an association with one of the variants (rs1801213) was observed when we considered the incidence of all hyperglycaemic events (NFG to IFG, NFG to Comparisons are analysis of covariance, adjusted for sex, age and BMI, and computed with log-transformed data a Indicates the statistical significance observed in the regression model for a crossed compound covariable 'glycaemic status-genotype' diabetes or IFG to diabetes change) during follow-up. The variants were also associated with the prevalence of IFG and/or diabetes at baseline. Together, these results suggest that allelic variations of WFS1 increase the risk of diabetes, but have a lesser impact on the risk of IFG in the DESIR cohort. Associations with diabetes were confirmed in crosssectional studies of three cohorts of type 2 diabetic patients compared with normoglycaemic controls. The most frequent haplotype at the haplotype block containing the WFS1 gene was associated with an increased risk of diabetes in the prospective study and with the prevalence of diabetes in cross-sectional studies.
Our results are in agreement with data from the literature. Sandhu and co-workers identified associations of the major alleles of rs10010131, rs6446482, rs752854 and rs734312 SNPs with WFS1 and diabetes risk in 9,533 cases and 11,389 controls from UK and Ashkenazi populations [11] . Lyssenko and co-workers observed an association between the major allele of rs10010131 and an increased risk of diabetes in two prospective cohorts with a median follow-up of 23.5 years and including 16,061 Swedish and 2,770 Finnish participants [13] . An association between rs752854 and type 2 diabetes was also observed in a Swedish cross-sectional study of 1,296 cases and 1,412 controls, with the minor allele conferring protection against diabetes [12] . Other studies have yielded less conclusive results. Florez and co-workers examined the effects of the rs10010131, rs752854 and rs734312 variants on diabetes incidence and response to interventions in the Diabetes Prevention Program, in which a lifestyle intervention or metformin treatment was compared with placebo [28] . They found no statistically significant interactions between genotypes and Diabetes Prevention Program intervention for any of the SNPs. None showed a statistically significant effect on diabetes incidence in the entire cohort, although in the lifestyle arm homozygosis for the minor alleles was consistent with protection from diabetes. Only a trend towards association with diabetes was observed for the rs10010131 variant in a Chinese cross-sectional study of 1,849 type 2 diabetic patients and 1,785 controls [16] . Although it is clear that WFS1 mutations cause diabetes [7, 8] , the genetic basis of the association of these common WFS1 variants with type 2 diabetes is still unclear. A recent fine-mapping study in UK, Swedish and Ashkenazi populations identified six novel, highly correlated SNPs showing strong and comparable associations with type 2 diabetes risk [29] . None had obvious functional properties that could predict deleterious effects on protein function. Given the strong linkage disequilibrium in the WFS1 region, the authors suggested that further refinement of these associations for identification of the variants responsible for increased diabetes risk would require studies in ethnically diverse populations and/ or studies with much larger sample sizes (10,000 to 100,000 individuals) [29] .
We also observed statistically significant associations of the risk alleles of the three SNPs with higher FPG and HbA 1c levels, and lower HOMA%B levels, both at baseline and throughout the study in participants who developed hyperglycaemia or type 2 diabetes. Interestingly, no allelic association with these intermediate phenotypes was observed in individuals who remained normoglycaemic at the end of the follow-up. The design of our study had some intrinsic limitations. Glucose tolerance status of participants was based on FPG only and not on an OGTT. Second, insulin secretion and insulin sensitivity were assessed by HOMA indices, which provide only an estimation of these variables. Nonetheless, we do not believe that these limitations have substantially biased our results, as they are in agreement with other observations. Sparso and coworkers observed a similar interaction between the glycaemic status and the genotype effect of rs734312 on insulin secretion in the Inter99 cohort, which involved 4,568 glucose-tolerant individuals and 1,471 individuals with treatment-naive abnormal glucose regulation (IFG, impaired glucose tolerance or screen-detected diabetes) [14] . The risk allele was associated with a decrease in insulinogenic index and decreased 30 min serum insulin levels after an oral glucose load in individuals with abnormal glucose regulation, but not in participants with normal glucose tolerance. It seems that this interaction between glycaemic status and genotype might explain the heterogeneous results reported by previous studies of associations between WFS1 variants and insulin secretion. Schafer and co-workers studied 1,578 non-diabetic German individuals at increased risk of type 2 diabetes, i.e. persons with a history of gestational diabetes, IFG, impaired glucose tolerance or family history of type 2 diabetes in first-degree relatives [15] . They found that the rs10010131 risk allele was associated with reduced insulin secretion during an OGTT. Interestingly, insulin secretion in response to an IVGTT or a hyperglycaemic clamp was not different between genotypes. However, when the hyperglycaemic clamp was combined with a glucagon-like peptide 1 (GLP-1) infusion, first-and second-phase insulin secretion were significantly decreased in carriers of the risk allele. A study from the Netherlands with similar size and power, but performed in participants with normal glucose tolerance, observed no significant genotype effect on insulin secretion in response to GLP-1 and glucose infusion during a hyperglycaemic clamp [17] . Other studies in large cohorts of non-diabetic Finnish [18] or Chinese [16] participants observed no association between rs10010131 and insulin secretion during an OGTT.
WFS1 protects cells from the damaging effects of hyperactivation of ER stress signalling [3] . ER stress is caused by physiological and pathological stimuli that lead to accumulation of a large load of unfolded and misfolded proteins in the ER. For instance, physiological ER stress occurs in pancreatic beta cells during postprandial stimulation of insulin synthesis [30] . Activation of ER stress signalling is tightly regulated because hyperactivation or chronic activation of this signalling pathway can cause cell death by inducing apoptosis [31] . Recent results have shown that WFS1 has an important function in the tight regulation of ER stress through its interaction with activating transcription factor 6α (ATF6α), a key transcription factor implicated in ER stress signalling [3] . WFS1 recruits ATF6α to the proteasome, where in the absence of ER stress it undergoes degradation. In situations of ER stress, ATF6α is released from WFS1 in the ER membrane and translocates to the nucleus, where it upregulates stress signalling targets. As WFS1 is induced by ER stress, it causes eventual degradation of ATF6α when ER homeostasis is established.
A possible reason why WFS1 variants only associate with insulin secretion in individuals with abnormal glucose regulation is that these polymorphisms have only a minor impact on WFS1 function in physiological situations. Thus, their effect on insulin secretion can be best appreciated in situations of chronic activation of ER stress signalling, such as in participants with decreased insulin sensitivity and chronic stimulation of insulin synthesis. Moreover, participants with abnormal glucose regulation may have other stressors of beta cell function, including unfavourable alleles in other pancreatic beta cell genes, as well as glucotoxicity, lipotoxicity or defects in the potentiation of insulin secretion by incretins (GLP-1, glucose-dependent insulinotropic polypeptide) [32] , which could interact with susceptibility variants of WFS1 and aggravate ER stressmediated apoptosis. WFS1 risk alleles have been shown to be associated with reduced insulin response to oral, but not to intravenous glucose [14, 15] , and with reduced response to GLP-1 stimulation during hyperglycaemic clamps [15] . This suggests an incretin-related defect. GLP-1 not only enhances insulin secretion in response to glucose, but also directly modulates the ER stress response, preventing beta cell apoptosis and promoting beta cell adaptation and survival [32, 33] . At the present time, the mechanisms of the putative interaction of GLP-1 signalling and WFS1 on ER function are still unclear.
In conclusion, allelic variations in the WFS1 gene modulated insulin secretion in normoglycaemic French individuals at risk of developing type 2 diabetes and also increased the risk of type 2 diabetes in a 9 year prospective study. In our study, the most frequent haplotype at the haplotype block containing the WFS1 gene was associated with an increased risk of diabetes. The genetic basis of these associations is still unclear. Further studies with much larger sample sizes are required to identify the functional variants responsible for increased diabetes risk.
